Biochemical markers of bone turnover are influenced by recently sustained fracture.

Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Malmö, Lund University, Sweden.
Bone (Impact Factor: 4.46). 05/2005; 36(5):786-92. DOI: 10.1016/j.bone.2005.02.009
Source: PubMed

ABSTRACT In striving to refine the clinical utility of different markers of bone metabolism, we should take into account numerous confounders, many of which are well known, such as sampling time, fasting status, and bone density. One further confounder may be ongoing fracture healing and/or post-fracture immobilization, which at least theoretically should impose an increased bone formation and resorption. Since both recent fracture and high bone turnover are independent predictors for new fracture, we thought it of importance to define the potential influence of such fracture on markers of bone turnover. From a population-based cohort of 1604 women, all 75 years old (the OPRA-study), 1024 women attended a clinical examination. The bone metabolism was assessed in serum, by three markers of bone formation [bone-specific alkaline phosphatase (S-Bone ALP), intact and N-Mid osteocalcin (S-Total OC), and total carboxylated osteocalcin (S-cOC)], two markers of bone resorption [C-terminal cross-linked telopeptides of type I collagen (S-CTX) and tartrate-resistant acid phosphatase type 5b (S-TRACP5b)], and in urine by one marker of bone resorption [deoxypyridinoline/creatinine (U-DPD/crea)] and two putative markers of bone resorption [urinary osteocalcins (U-OC/crea)]. Current physical activity and retrospective fracture data were recorded by questionnaires. The fracture data, for the entire cohort of 1604 women, were validated with radiographic referrals and reports, saved since the beginning of the last century. All data provided, except date of occurrence of retrospectively sustained fracture, were thus obtained cross-sectionally and in all women at the age of 75. Fracture had ever been sustained by 727 of the entire cohort (n = 1604), and by 523 of the attending women (n = 1024). All markers were marginally higher (significant only for U-DPD/crea, P = 0.027) in women who had ever sustained fracture, compared to women without fracture. In women with recent retrospective fracture (since 2 years) (n = 100), the levels of all markers, except the two S-OCs, were significantly higher (r = 0.20-0.33, P = 0.049-0.001) the more recently the fracture had been sustained. Women with low current physical activity had elevated levels of U-DPD/crea (P < 0.001) and one U-OC (P = 0.014), while the other markers were unaffected.

Download full-text


Available from: Kaisa Ivaska, Dec 04, 2014
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study has investigated the effects of gold nanoparticles (Au NPs) on the proliferation, differentiation, and mineralization of a murine preosteoblast cell line MC3T3-E1 in vitro. The results show that Au NPs with diameters of both 20 and 40 nm promoted the proliferation, differentiation, and mineralization of MC3T3-E1 cells in a time- and dose-dependent manner at the concentrations of 1.5×10−5, 3.0×10−5, and 1.5×10−4 μmol/L. The reverse transcriptase polymerase chain reaction (RT-PCR) indicates that the expressions of runt-related transcription factor 2 (Runx2), bone morphogenetic protein 2 (BMP-2), alkaline phosphatase (ALP), and osteocalcin (OCN) genes increased after the 20 and 40 nm Au NP treatments, and the expression levels were higher than those of the NaF group. The above results suggest that Au NPs have the potential to promote the osteogenic differentiation and mineralization of MC3T3-E1 cells and the particle size plays a significant role in the process. Runx2, BMP-2, ALP, and OCN genes may interact with each other, further stimulating the osteogenic differentiation of MC3T3-E1 cells. Keywordsgold nanoparticles-proliferation-osteogenic differentiation-mineralization
    Chinese Science Bulletin 04/2010; 55(11):1013-1019. DOI:10.1007/s11434-010-0046-1 · 1.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bone metabolism can be assessed by measuring bone turnover markers in serum or urine. Bone turnover markers are substances released from bone during bone turnover. They can be skeletal tissue proteins, collagen fragments, peptides, or enzymes released from bone cells. Bone turnover markers are extensively used in research applications but also as tools for the management of skeletal disorders in clinical practice. Osteoporosis-related applications may include assessment of response to, or deciding on osteoporosis therapy; identification of individuals with increased bone loss, and prediction of risk for fragility fractures. Advancements in the development of assays to measure bone markers has made the measurements available also for clinical practice. The possibility to use them in various aspects of clinical practice has been tested in the recent years and given promising results. Monitoring the efficacy of bone-active drugs is currently the most promising application for bone turnover markers. Some markers, particularly resorption markers may also be useful in identifying individuals who are at high risk for bone loss and future fracture. In this article we discuss some potential applications of currently available bone turnover markers in postmenopausal osteoporosis.
    Clinical Reviews in Bone and Mineral Metabolism 03/2009; 8(1):1-14. DOI:10.1007/s12018-009-9042-x